Proprius Pharmaceuticals Inc., of San Diego, appointed David Anderson chief scientific officer.

pSivida Ltd., of Perth, Australia, appointed Michael Soja vice president, finance and chief financial officer; and Lori Freedman vice president, corporate affairs, general counsel and secretary.

QLT Inc., of Vancouver, British Columbia, appointed Ian Massey to its board and Peter O'Callaghan senior vice president, corporate development and general counsel.

Quantum Genomics Corp., of Jersey City, N.J., appointed Lionel Segard CEO.

ResVerlogix Corp., of Calgary, Alberta, appointed Kelly McNeill chief financial officer and Theresa Kennedy vice president corporate communications.

Rigel Pharmaceuticals Inc., of South San Francisco, appointed Ryan Maynard vice president of finance and acting chief financial officer.

Sangamo BioSciences Inc., of Richmond, Calif., appointed Ward Wolff to its board.

Solazyme, of Menlo Park, Calif., appointed Tony Day vice president of research and development.